ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 731

Prediction of Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis

Wanlong Wu1, Suzana Jordan2, Mike Oliver Becker3, Rucsandra Dobrota3, Shuang Ye4, Britta Maurer5 and Oliver Distler2, 1Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich; Department of Rheumatology, Renji Hospital South Campus, Shanghai Jiao Tong University School of Medicine, Zurich, Switzerland, 2Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 3Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, 4Department of Rheumatology, Renji Hospital South Campus, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, 5Department of Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Arthritis, Computed tomography (CT), fibrosis, interstitial lung disease and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

No data are available to distinguish between progressive and stable patients when mild lung fibrosis is diagnosed in systemic sclerosis (SSc) patients. This study aimed to identify clinical and laboratory parameters that can predict the progression of interstitial lung disease (ILD) within 1 year in patients with mild SSc-ILD.

Methods:

Data prospectively collected in our local SSc cohort were analyzed in this observational study. Inclusion criteria were: diagnosis of SSc fulfilling ACR/EULAR 2013 criteria, diagnosis of ILD by HRCT, < 20% lung involvement extent on HRCT at the first visit (baseline), available HRCT and pulmonary function tests at baseline and annual follow-up visits (12±3 months), no concomitant with PAH.

The primary endpoint, progression of ILD was defined if any of the following parameters was fulfilled : > 20% extent of lung involvement on HRCT at any follow-up visit, decrease in FVC ≥15% within 1 year, or decrease in FVC ≥ 10% and DLCO ≥ 15% within 1 year.

Candidate predictors for logistic regression were selected by expert opinion based on clinical consideration. Receiver Operating Characteristic (ROC) curve analysis was performed to determine the optimal cut-off value for each significant continuous parameter.

Results:

From the 81 patients included, 25 (30.9%) had progression of ILD. Differences of parameters between progressors and non-progressors were analyzed by univariate analysis (Table 1).

Three candidate predictors reflecting the overall disease severity including worst SpO2 during 6-minute walk test (6MWT), arthritis ever and modified Rodnan skin score (mRSS) were selected for logistic regression by expert opinion. The final regression model identified worst SpO2 (p=0.011, OR: 0.78, 95% CI 0.64 to 0.94) and arthritis ever (p=0.002, OR: 7.15, 95% CI 2.01 to 25.48) as independent predictors. The ROC curve analysis identified the best cut-off value for worst SpO2 as 94% (area under the curve: 0.78, sensitivity 0.667, specificity 0.857).

By employing combination of both predictors, the prediction model increased the prediction success rate from 30.9% in the whole cohort to 100% in the optimized enrichment cohort (Table 2).

Conclusion:

Our study identified exercise-induced SpO2 decline and arthritis ever as independent predictor of progression of mild SSc-ILD within 1 year. The derived evidence-based prediction model might be helpful for the risk stratification of this subgroup in clinical practice and cohort enrichment for future clinical trial design.


Disclosure: W. Wu, None; S. Jordan, None; M. O. Becker, None; R. Dobrota, None; S. Ye, Continent Pharmaceutical Company (China), 2; B. Maurer, AbbVie, Protagen, EMDO, Novartis, German SSc Society, Pfizer, Roche, Actelion, MSD, 5,mir-29 for the treatment of systemic sclerosis, 9; O. Distler, 4 D Science, Actelion, Active Biotec, Bayer, Biogen Idec, Boehringer Ingelheim Pharma, BMS, ChemomAb, EpiPharm, Ergonex, espeRare foundation, GSK,Roche-Genentech, Inventiva, Lilly, medac, MedImmune, Mitsubishi Tanabe, Pharmacyclics, Pfizer, Sanofi, Seroda, 2.

To cite this abstract in AMA style:

Wu W, Jordan S, Becker MO, Dobrota R, Ye S, Maurer B, Distler O. Prediction of Progression of Interstitial Lung Disease in Patients with Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prediction-of-progression-of-interstitial-lung-disease-in-patients-with-systemic-sclerosis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prediction-of-progression-of-interstitial-lung-disease-in-patients-with-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology